Try our Advanced Search for more refined results

Expert Analysis

Revisiting Ariad V. Eli Lilly

Law360 (August 10, 2009, 2:30 PM EDT) -- On April 3, 2009, the Federal Circuit issued its decision in Ariad Pharmaceuticals Inc. v. Eli Lilly & Co., 560 F.3d 1366 (Fed. Cir. 2009), in which the court held, inter alia, that claims directed to a method of reducing Nuclear Factor Kappa B ("NF-kB") activity in cells were invalid for failing to satisfy the written description requirement under 35 U.S.C. § 112, paragraph 1....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!